Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: Implications for ALK inhibitor therapy

Cancer

Volumn 119, Issue 22, 2013, Pages 3968-3975

  Ross Camidge, D ^a,c   Skokan, Margaret ^a   Kiatsimkul, Porntip ^a   Helfrich, Barbara ^a   Lu, Xian ^b   Barõn, Anna E ^b   Schulte, Nathan ^a   Maxson, Delee ^a   Aisner, Dara L ^a   Franklin, Wilbur A ^a   Doebele, Robert C ^a   Varella Garcia, Marileila ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Global Health and Health Disparities   (United States)

^c Anschutz Cancer Pavilion   (United States)

Author keywords

anaplastic lymphoma kinase; borderline; copy number; crizotinib; florescence in situ hybridization

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB;

ARTICLE; CANCER CELL CULTURE; CELL COUNT; CONTROLLED STUDY; DRUG SENSITIVITY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

ANAPLASTIC LYMPHOMA KINASE; BORDERLINE; COPY NUMBER; CRIZOTINIB; FLORESCENCE IN SITU HYBRIDIZATION;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; DNA COPY NUMBER VARIATIONS; GENE REARRANGEMENT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84887127751     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28311     Document Type: Article

References (20)

1. Camidge DR, Doebele RC,. Treating ALK-positive lung cancer-early successes and future challenges. Nat Rev Clin Oncol. 2012; 9: 268-267.
2. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363: 1693-1703.
3. Kim D-W, Ahn M-J, Shi Y, et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2012; 30 (15 suppl). Abstract 7533.
4. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated Results from a phase 1 study. Lancet Oncol. 2012; 13: 1011-1019.
5. Camidge DR, Kono SA, Flacco A, et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res. 2010; 16: 5581-5590.
6. Weickhardt AJ, Aisner DL, Franklin WA, et al. Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer. Cancer. 2013; 119: 1467-1477.
7. Camidge DR, Theodoro M, Maxson DA, et al. Correlations between the percentage of tumor cells showing an ALK (anaplastic lymphoma kinase) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer. Cancer. 2012; 118: 4486-4494.
8. Webb TR, Slavish J, George RE, et al. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther. 2009; 9: 331-356.
9. Peled N, Palmer G, Hirsch FR, et al. Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer [serial online]. J Thorac Oncol. 2012; 7: e14-e16.
10. Sun JM, Choi YL, Won JK, Hirsch FR, Ahn JS, Ahn MJ, Park K,. A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK [serial online]. J Thorac Oncol. 2012; 7: e36-e38.
11. Yoshida A, Tsuta K, Nitta H, et al. Bright-field dual-color chromogenic in situ hybridization for diagnosing echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinomas. J Thorac Oncol. 2011; 6: 1677-1686.
12. Doebele RC, Pilling AB, Aisner D, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012; 18: 1472-1482.
13. Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers [serial online]. Sci Transl Med. 2012; 4: 120ra17.
14. Salido M, Pijuan L, Martinez-Aviles L, et al. Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. J Thorac Oncol. 2011; 6: 21-27.
15. Khadija K, Auger N, Lueza B, et al. ALK amplification and crizotinib sensitivity in non-small cell lung cancer cell lines and patients report [abstract]. J Clin Oncol. 2012; 30 (suppl). Abstract 10556.
16. Tan W, Wilner KD, Bang Y, et al. Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients [abstract]. J Clin Oncol. 2010; 28 (suppl). Abstract 2596.
17. Shaw AT, Kim D-W, Nakagawa K, et al. Phase III study of crizotinib vs pemetrexed or docetaxel chemotherapy in patients with advanced ALK-positive NSCLC (PROFILE 1007) [abstract]. Paper presented at: 37th European Society for Medical Oncology (EMSO) Congress; September 28 to October 2, 2012; Vienna, Austria. Abstract 2682.
18. Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib [serial online]. J Clin Oncol. 2011; 29: e443-e445.
19. Weickhardt AJ, Scheier B, Burke JM, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012; 7: 1807-1814.
20. Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012; 18: 382-384.